What is it about?
Serum Serum Golgi protein 73 levels were positively correlated with the progression of chronic liver disease, including inflammation and fibrosis/cirrhosis, but most of them were mainly focused on HBV infection related liver disease nor HCV. For the first time, we have explored the diagnostic potential of serum GP73 for HCV-related liver lesions in two cohorts.
Featured Image
Photo by Online Marketing on Unsplash
Why is it important?
Our results provided that serum GP73 were comparable to serum ALT and AST in diagnosing the liver necroinflammation grade at G≥2, but its diagnostic values for advanced fibrosis (F≥3) and cirrhosis (F=4) were limited when compared to APRI and FIB-4 in chronic HCV infection-related disease. And also, we found that an obvious elevation of serum GP73 after patients receiving PEG-IFN and ribavirin treatment, which suggests that serum GP73 could not truly reflect the situation of liver injury when used in clinical practice for patients with PEG-IFN and ribavirin treatment and clinicians should be more cautious.
Perspectives
Serum GP73 is an important indicator in evaluating and monitoring the disease progression including liver necroinflammation and fibrosis in patients with chronic HCV infection. Serum GP73 has a certain value in diagnosing liver necroinflammation (G≥2). However, it is limited for serum GP73 in diagnosing advanced fibrosis (F≥3) and cirrhosis (F=4) in comparison with APRI and FIB-4.
Xiangjun Qian
Read the Original
This page is a summary of: Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries, Disease Markers, September 2019, Hindawi Publishing Corporation,
DOI: 10.1155/2019/3862024.
You can read the full text:
Resources
Contributors
The following have contributed to this page
